I-Semaglutide iyisidakamizwa esehlisa i-glucose esakhiwe nguNovo Nordisk ekwelapheni uhlobo 2 sikashukela. NgoJuni 2021, i-FDA igunyaze i-Semaglutide ukuze imakethwe njengomuthi wokwehlisa isisindo (igama lokuhweba elithi Wegovy). Umuthi uyi-glucagon-like peptide 1 (GLP-1) receptor agonist engakwazi ukulingisa imiphumela yayo, inciphise indlala, futhi ngaleyo ndlela inciphise ukudla kanye nekhalori, ngakho iyasebenza ekwehleni kwesisindo.
Ngaphandle kokusetshenziselwa ukwelapha uhlobo lwe-2 yesifo sikashukela nokukhuluphala, i-Semaglutide itholakale futhi ivikela impilo yenhliziyo, ukunciphisa ingozi yomdlavuza, nokusiza ukuyeka ukuphuza. Ngaphezu kwalokho, izifundo ezimbili zakamuva zibonise ukuthi i-Semaglutide nayo inganciphisa ingozi yesifo sezinso esingapheli nesifo se-Alzheimer's.
Ucwaningo lwangaphambilini lubonise ukuthi ukuncipha kwesisindo kungakhulula izimpawu ze-knee osteoarthritis (kuhlanganise nokukhululeka kobuhlungu). Kodwa-ke, imiphumela yezidakamizwa ze-GLP-1 receptor agonist zokulahlekelwa isisindo njengeSemaglutide emiphumeleni ye-knee osteoarthritis kubantu abakhuluphele ayizange ifundwe ngokugcwele.
Ngomhla zingama-30 kuMfumfu, i-2024, abacwaningi baseNyuvesi yaseCopenhagen naseNovo Nordisk bashicilela iphepha lokucwaninga elinesihloko esithi: Kanye-Weekly Semaglutide in Persons With Obesity and Knee Osteoarthritis in the New England Journal of Medicine (NEJM), iphephabhuku eliphezulu lezokwelapha lamazwe ngamazwe.
Lolu cwaningo lomtholampilo lubonise ukuthi i-semaglutide inganciphisa kakhulu isisindo futhi inciphise kakhulu ubuhlungu obubangelwa i-knee arthritis ehlobene nokukhuluphala (umphumela we-analgesic ulingana ne-opioids), futhi uthuthukise ikhono labo lokubamba iqhaza kwezemidlalo. Kungokokuqala futhi ukuthi kuqinisekiswe uhlobo olusha lomuthi wokwehlisa isisindo, i-GLP-1 receptor agonist, luqinisekiswa ukuthi lwelaphe isifo samathambo.
Isikhathi sokuthumela: Feb-27-2025